Directed issue of new shares in Biotie Therapies Corp. to
institutional investors
(Thomson Reuters ONE) - BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 4 DECEMBER 2009at 9.10 p.m.Directed issue of new shares in Biotie Therapies Corp. toinstitutional investorsNot for release, publication or distribution, directly or indirectly,in whole or in part, in or into the United States, Australia, Canada,Japan or South Africa.The Board of Directors of Biotie Therapies Corp. ("Biotie" or"Company") has decided to offer a maximum of 14,432,000 new shares inBiotie through a directed share issue against cash payment. Thesubscription price is EUR 0.50 per share.The new shares will be offered in deviation from the shareholders'pre-emptive subscription right to a limited number of institutionalinvestors in Finland and internationally (the "Offering"). Biotie hasengaged Nomura Code Securities Limited to act as the lead manager inconnection with the Offering. The Offering is made in order tostrengthen Biotie's working capital, to provide further financing forthe Company's R&D programs and to extend the Company's shareholderbase.The subscription period will end on 7 December 2009 at 11 a.m.(Finnish time). In the event of oversubscription, the Offering may becompleted prematurely. The subscription price of EUR 0.50 per sharewas determined by the Board of Directors on the basis of the currentprice of Biotie's share in the trading on the NASDAQ OMX Helsinkistock exchange, and based on the recommendation by the lead manager.The new shares are offered based on the authorisation by theExtraordinary General Meeting of Shareholders of Biotie held on 29October 2009. The new shares will amount to approximately 9.99 percent of the total number of shares and votes in Biotie before theOffering, and approximately 9.1 per cent of the total number ofshares and votes in Biotie after the Offering provided that theOffering is subscribed in full. The subscription price of the newshares will be registered in its entirety to the share capital ofBiotie.In Turku, 4 December 2009Biotie Therapies Corp.The Board of DirectorsFor further information, please contact:Virve Nurmi, Investor Relations Managertel. +358 2 274 8900, e-mail: virve.nurmi(at)biotie.comwww.biotie.comDISTRIBUTION:NASDAQ OMX Helsinki LtdMain MediaDISCLAIMER:The information herein may not be distributed or sent into the UnitedStates, Australia, Canada, Japan or South Africa. The informationcontained herein shall not constitute an offer to sell or thesolicitation of an offer to buy, nor shall there be any sale of thesecurities referred to herein in any jurisdiction in which suchoffer, solicitation or sale would be unlawful prior to registration,exemption from registration or qualification under the securitieslaws of any such jurisdiction.The information contained herein does not constitute an offer ofsecurities for sale in the United States. The securities referencedin this release may not be offered or sold in the United Statesabsent registration or an exemption from registration as provided inthe United States Securities Act of 1933, as amended, and the rulesand regulations thereunder. Biotie Therapies Corporation does notintend to register any portion of the placement in the United Statesor to conduct a public offering of any securities in the UnitedStates.This communication does not constitute an offer of securities to thepublic in the United Kingdom. This communication is directed only at(i) persons who are outside the United Kingdom, (ii) persons who haveprofessional experience in matters relating to investments fallingwithin Article 19(5) of the Financial Services and Markets Act 2000(Financial Promotion) Order 2005 (the "FP Order") and (iii) high networth entities falling within Article 49(2) of the FP Order, andother persons to whom it may lawfully be communicated, (all suchpersons together being referred to as "relevant persons"). Anyinvestment activity to which this communication relates will only beavailable to, and will only be engaged with, relevant persons. Anyperson who is not a relevant person should not act or rely on thisdocument or any of its contents.Nomura Code Securities Limited ("Nomura") is acting exclusively forBiotie Therapies Corporation and no one else in connection with theplacing. It will not regard any other person (whether or not arecipient of this release) as its respective and will not beresponsible to anyone other than Biotie Therapies Corp for providingthe protections afforded to its clients, nor for giving advice inrelation to the placing or any transaction or arrangement referred toherein. No representation or warranty, express or implied, is made byNomura as to the accuracy, completeness or verification of theinformation set forth in this release.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 04.12.2009 - 20:10 Uhr
Sprache: Deutsch
News-ID 9317
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 464 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Directed issue of new shares in Biotie Therapies Corp. to
institutional investors"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotie Therapies Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
